3-V Biosciences Completes $20 Million Series C Financing
Menlo Park, California, June 21, 2013. 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key pathways in oncology […]
PRESS RELEASES
PRESS RELEASES
PRESS RELEASES
3–V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012
Small Molecule FASN Inhibitors Demonstrate Antiviral Activity Menlo Park, California, November 10, 2012. 3–V Biosciences, Inc., announced today that preclinical
PRESS RELEASES
3‐V Biosciences To Present Data on HCV Product Candidates at the American Association for the Study of Liver Disease Annual Meeting 2012
Menlo Park, California, October 1, 2012. 3‐V Biosciences, Inc., announced today that two abstracts have been accepted for presentation at
PRESS RELEASES
3‐V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
Menlo Park, California, July 10, 2012. 3-V Biosciences, Inc., announced today that George Kemble, PhD, Chief Scientific Officer, will present
PRESS RELEASES
3-V Biosciences Closes Preferred Stock Financing and Designates Novel Host-Factor Hepatitis C Program
Menlo Park, California, January 5, 2012. 3-V Biosciences, Inc. announced today both the closing of a Preferred Stock financing and the
PRESS RELEASES
3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
Menlo Park, California, June 29, 2012. 3-V Biosciences, Inc., announced today the appointment of Douglas Buckley, PhD, as Vice President
PRESS RELEASES
3-V Biosciences Appoints Dr. George W.Kemble, PhD, as Chief Scientific Officer
Menlo Park, California, August 15, 2011. 3-V Biosciences, Inc. announced today the appointment of Dr. George W. Kemble, PhD as
PRESS RELEASES
3-V Biosciences Promotes Stephen R.Brady to Chief Business Officer
Menlo Park, California, February 10, 2011. 3-V Biosciences, Inc. announced today Stephen R. Brady has been named as Chief Business
PRESS RELEASES
3-V Biosciences Appoints Merdad V. Parsey, MD, PhD, as Chief Executive Officer
Menlo Park, California, September 30, 2010. 3-V Biosciences, Inc. announced today the appointment of Merdad V. Parsey, MD, PhD as
PRESS RELEASES
James F. Young joins 3-V Biosciences Board of Directors
Menlo Park, California, July 20, 2010. 3-V Biosciences, Inc. today announced the appointment of James F. Young, Ph.D. to its
